Ospedale regionale di Lugano

Running trials

• Recruiting

  Patient-Reported Quality of Life After Open Surgery for Complex Abdominal Aortic Aneurysms: A Prospective Study

  NCT07580443· Prouse Giorgio· Source

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

  NCT06891066· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.

  NCT06776172· University Hospital, Basel, Switzerland· Source

• Active, not recruiting

  Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

  NCT06700343· Phase 3· Amgen· Source

• Recruiting

  Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study

  NCT06689956· Mayo Clinic· Source

• Active, not recruiting

  Consolidation Therapy With Cladribine in Relapsing Multiple Sclerosis Patients

  NCT06854094· Ente Ospedaliero Cantonale, Bellinzona· Source

• Recruiting

  AI-assisted Migraine Education: Efficacy, Safety and Patients' Acceptance

  NCT06507150· Ente Ospedaliero Cantonale, Bellinzona· Source

• Recruiting

  Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage.

  NCT06163573· Phase 2· University Hospital, Basel, Switzerland· Source

• Active, not recruiting

  A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

  NCT05766501· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

  NCT05631093· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  MultiSCRIPT-Cycle 1: Personalized Medicine in Multiple Sclerosis - Pragmatic Platform Trial Embedded Within the SMSC

  NCT06095271· University Hospital, Basel, Switzerland· Source

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

  NCT05476926· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

  NCT05399888· Phase 2· Biogen· Source

• Active, not recruiting

  A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

  NCT05269004· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  DreaMS - Validation Study 1

  NCT05009160· Research Center for Clinical Neuroimmunology and Neuroscience Basel· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

  NCT04586010· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

  NCT04544436· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Surgery for Recurrent Glioblastoma

  NCT02394626· Phase 2· Insel Gruppe AG, University Hospital Bern· Source

• Active, not recruiting

  Ischaemic PReconditioning In Non Cardiac surgEry

  NCT02427867· Università Vita-Salute San Raffaele· Source

• Enrolling by invitation

  Juvenile Inflammatory Rheumatism (JIR) Cohorte

  NCT02377245· Michaël Hofer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Aortic aneurysm1 recruiting
• Childhood cancers1 recruiting
• Endometrial cancer1 recruiting
• Glioblastoma1 recruiting
• Migraine1 recruiting
• Osteoarthritis1 recruiting
• Prostate cancer1 recruiting
• Rheumatoid arthritis1 recruiting

Closed trials

• Completed

  A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

  NCT05798520· Phase 2· Biogen· Source

• Completed

  Evaluation of Standard of Care Practices, Procedural Outcomes and In-hospital Complications of Peripheral Endovascular Procedures

  NCT05831319· Biotronik AG· Source

• Completed

  Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

  NCT05499832· Phase 3· Insel Gruppe AG, University Hospital Bern· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Terminated

  A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

  NCT05161481· Phase 2· Boehringer Ingelheim· Source

• Completed

  TMS Treatment of Social Cognition Skills in Mild Cognitive Impairment

  NCT04490616· Ospedale Regionale di Lugano· Source

• Completed

  A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.

  NCT04760990· University Hospital, Basel, Switzerland· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source

• Completed

  Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)

  NCT04934800· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

• Completed

  Decompressive Hemicraniectomy in Intracerebral Hemorrhage

  NCT02258919· Insel Gruppe AG, University Hospital Bern· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Narcolepsy4 works · 0 trials